Shaji K. Kumar, MD
Clinical Research Office
Mayo Clinic Cancer Center
Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr. Kumar is a Consultant in the Division of Hematology and Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, Minnesota. He serves as Medical Director for the Mayo Clinic Cancer Center Clinical Research Office.
Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee and as Chair of the NCCN Multiple Myeloma Guidelines Panel. His research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
Dr. Shaji Kumar has received institutional payments for his role as a consultant and ad board participant from AbbVie Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Genentech - A Member of the Roche Group, Janssen Pharmaceuticals, Inc., Kite Pharma, and Takeda Oncology. He has received honoraria for his role as a consultant/ad board participant from Oncopeptides, Beigene and Antegene Corporation. He has received research support for Mayo Clinic Cancer Center and served as the principal investigator for clinical trials from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, CARsgen Therapeutics, Genentech, Janssen, Kite, Merck & Co., Inc., Novartis AG, Takeda Oncology, and TeneoBio.